New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMOTS-c vs Bronchogen

MOTS-c vs Bronchogen

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
MOTS-c
Anti-Aging & Longevity
Bronchogen
Summary
MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
Half-Life
Estimated 1–2 hours
Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
5–15 mg
10 mg per day
Frequency
3–5 times per week
Daily for 10–30 days
Key Benefits
  • Improves insulin sensitivity and glucose metabolism
  • Enhances exercise capacity and endurance
  • Reduces age-related metabolic decline
  • Activates AMPK — the master metabolic regulator
  • Promotes fat oxidation
  • Anti-inflammatory effects
  • May extend healthspan via mitochondrial optimization
  • Increases energy and reduces fatigue
  • Tissue-specific support for bronchial and lung health
  • Promotes normalization of bronchial epithelial cell function
  • Potential benefits in chronic bronchitis and COPD support
  • Anti-aging effects on pulmonary tissue
  • May reduce frequency of respiratory infections
  • Supports lung function preservation with aging
  • Compatible with other Khavinson bioregulator peptides
Side Effects
  • Injection site irritation
  • Fatigue during initial adaptation
  • Unknown long-term profile (limited human data)
  • Generally well tolerated in research studies
  • Mild local reactions at injection site (if injected)
  • No significant systemic side effects reported at standard doses
Stacks With